Skip to main content
Home
  • 服务
    服务

    我们的服务涵盖产品开发和商业化的整个生命周期,既适用于小型本地试验,也适用于大型全球项目。

    Read More
    临床研究服务 商业定位 咨询服务 早期服务 战略性解决方案 语言服务 实验室服务 医学影像服务 真实世界洞察 研究中心及患者解决方案
    clinical-trials-china.jpeg
    COVID-19的临床试验

    Clinical trials during COVID-19.

    clinical-trials-china-2.jpeg
    研究中心和患者

    研究中心和患者识别,入组和参与

  • 治疗领域
    治疗领域

    我们在广泛的治疗领域拥有丰富的经验。我们管理所有主要地区的研究,与世界领先的研究人员建立了稳固的工作关系。

    Read More
    心血管系统 细胞和基因疗法(CGT) 中枢神经系统 内分泌与代谢疾病 感染性疾病 内科与免疫学 医疗器械 肿瘤学 儿科学 罕见病与孤儿病 移植免疫学 女性健康
    icon-china-mega-menu-image.jpeg
    疫苗

    ICON 领导了 18 种疫苗的开发,获得了 FDA/EMA 的批准,其中包括世界上第一个获批的 COVID-19 疫苗

    icon-china-mega-menu-image-2.jpeg
    治疗领域洞察

    ICON 的治疗专家定期为行业出版物内容做出贡献。

  • 加入我们
  • 新闻和活动
  • ICON中国
    ICON中国
    Read More
    ICON中国 公司历史 我们的荣誉 Leadership 联系我们
    esg-mdd.jpg
    环境、社会与公司治理(ESG)

    ICON Cares 代表我们致力于关爱每一个人、环境与社区,并带来积极改变的承诺。

    healthcare-intelligence-video-poster.png
    医疗智能赋能

    推动临床研究不断前行

  • 中国大陆办公室
  • 商务合作
  1. Home
  2. 新闻和活动
  3. 活动一览
  4. Webinars
  5. Meeting Evidentiary Needs with Electronic Health Records

Meeting Evidentiary Needs with Electronic Health Records

Transformative applications in observational studies and pragmatic clinical trials

  • Date 25 October 2016
    Time 11:00 - 12:00
    Location Webinar
    Timezone America/Bogota

On-Demand Webinar Archive

To access the archived recording of this webinar, visit our webinar channel and complete a one time only form. This will give you access to our entire library of archived webinars.

Access Webinar Archive

As the healthcare system continues to progress in the use of technology to track and improve patient care, Electronic Health Record (EHR) systems are becoming a burgeoning source of Real-World Data (RWD) for researchers and manufacturers alike.

EHRs can be a cost-effective way to identify, access and analyse data needed for peri- and post-approval research studies. In this webinar, we will focus on how RWD can be quickly applied to Observational Studies and Pragmatic Clinical Trials (PCTs), as well as what challenges researchers face in successful application of RWD to these studies.

Key insights

This webinar will discuss the advancements, opportunities, and challenges around the current and future use of Real-World Data from EHR systems in observational studies and pragmatic clinical trials. Attendees will gain valuable insights on:

The current demand for Real World Data to provide post-approval reporting and inform manufacturer business decisions
Development of RWD guidelines and requirements by regulators in the US and EU markets
How RWD is being applied to post-marketing research including observational trials and Pragmatic Clinical Trials

Key speakers

  • Jim Carroll - Vice President, Real World Evidence
  • Rob Sambrook - Divisional Principal, CS&S Epidemiology

Observational studies and pragmatic clinical trials

Observational Studies, being non-interventional in nature, have traditionally been conducted by collecting data via the establishment of patient registries. This can be an expensive start-up process and long term management can be cumbersome. As EHR databases continue to grow and offer an abundance of RWD, their use as viable sources for retrospective and prospective analyses can grow as well with less cost and resourcing impact.

Pragmatic Clinical Trials (PCTs) are known for having broader eligibility criteria than Randomized Clinical Trials (RCTs) and are conducted on a much larger patient group in order to produce more generalized population-based results. Identifying patients for PCTs can be a laborious process that requires dependence on providers’ initiative to drive patient recruitment.

EHR systems are becoming the backbone of PCTs and provide a method to identify, enroll, and monitor patients while capturing treatment details and outcomes for study as the trial continues. In this case, use of the EHR system can reduce the cost of these studies through automating the patient identification process as well as others.  

EHR challenges

While EHRs demonstrate a great benefit to the post-approval clinical research community, challenges do exist, some of which will be addressed as EHR technology progresses and some of which are inherent to any secondary data source. Researchers will have to be aware of these nuances in data capture and system interoperabilities to leverage the usefulness of EHRs in conducting scientifically sound studies and trials.

As EHR-driven studies advance with this ever-present RWD source, biopharmaceutical, medical device and diagnostic manufacturers should look to the benefit these studies can provide to stay ahead of the curve with real-world evidence that supports the value of their marketed products in continuing to expand access and support reimbursement. 

Target audience

  • EPI
  • HEOR
  • Market Access
  • Pricing & Contracting
In this section
In this section
  • In the News
  • Press releases
  • 活动一览
    • Industry events
    • Webinars
    • Workshops
  • DIA China 2022

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media
Site Branding
    ICON plc
  • Contact
  • Results & Reports
For Clients
  • 我们的服务
  • 治疗领域
ICON for
  • 新 闻
  • 加入我们
News & Events
  • 中国大陆办公室
  • 商务合作
Socials
  • WeChat QR code

Legal Footer

  • © 2025 ICON plc
  • Disclaimer
  • Privacy
  • Cookies
How can we help?
  • All
Popular search terms:
  • COVID-19
  • Site & Patient Recruitment
  • Oncology
  • Medical Device
  • Real World Evidence
  • Decentralised & hybrid clinical trials
  • Digital Disruption